MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
Revolutionizing Multiple Myeloma Treatment: AI-Driven Cardiac Risk Stratification for CAR T-Cell Therapy
Leveraging advanced cardiac imaging and biomarkers, our AI analysis reveals how the MyCARdiac score precisely predicts outcomes and guides surveillance for RRMM patients undergoing cilta-cel, minimizing off-target toxicities and enhancing treatment efficacy.
Executive Impact: Quantifying the Predictive Power
Understanding the critical metrics behind cardiac risk stratification in CAR T-cell therapy provides a clear view of its clinical and operational value.
0
Patients with Baseline Cardiac Disease
0
PFS Hazard Ratio (High-Risk MyCARdiac)
0
OS Hazard Ratio (High-Risk MyCARdiac)
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
MyCARdiac Score: A New Standard for Risk Stratification
The MyCARdiac score provides a critical advancement in identifying RRMM patients at high risk for adverse outcomes following cilta-cel therapy. By integrating routine cardiac imaging and biomarker data, it offers a personalized risk assessment that informs pre-treatment workup and guides post-infusion surveillance, enhancing patient safety and optimizing therapeutic strategies.
Integrating Multi-Modal Cardiac Data
The MyCARdiac score synthesizes data from echocardiography (LVEF, LVPWd, LVM-Index), computed tomography (CAC score), and NT-proBNP levels. These parameters, when combined, offer a comprehensive view of cardiac health, capturing aspects of LV remodeling, atherosclerosis, and subclinical congestion. A patient is classified as high-risk if at least two parameters exceed predefined cut-off values.
Enhanced Prediction of PFS and OS
The MyCARdiac score demonstrates superior predictive power for progression-free survival (PFS) and overall survival (OS) compared to existing assessments like the HFA-ICOS score. Patients identified as high-risk by MyCARdiac show significantly shorter PFS and OS, highlighting its utility in identifying those who require more intensive monitoring and potentially modified treatment approaches.
Cardiac Health, Disease Burden, and CAR T-cell Dynamics
High-risk MyCARdiac patients exhibit elevated baseline and post-infusion sBCMA and IL-6 levels, indicating a greater disease burden and inflammatory response. Crucially, these patients also show impaired CAR T-cell expansion, suggesting a biological link between baseline cardiac health, disease aggressiveness, and the efficacy of CAR T-cell therapy. This multifactorial association underscores the importance of a holistic patient assessment.
16.7%
of patients in the study were classified as high-risk by the MyCARdiac score (≥2 abnormal cardiac parameters).
MyCARdiac Score Development & Application Workflow
Routine Echocardiography
→
Pre-treatment CT Scans (CAC)
→
NT-proBNP Measurement
→
Integrate Parameters & Determine MyCARdiac Score
→
Risk Stratification (High-risk if ≥2 values)
→
Guide Post-infusion Surveillance & Treatment Decisions
| Feature | MyCARdiac Score | HFA-ICOS Assessment |
|---|---|---|
| PFS Hazard Ratio (HR) | 9.98 (95% CI 1.82-54.6, p=0.00797) | 4.71 (95% CI 0.55-40.36, p=0.157, not significant) |
| OS Hazard Ratio (HR) | 6.75 (95% CI 1.13-40.44, p=0.0365) | (p=0.0404, HR not specified) |
| Key Strengths |
|
|
MyCARdiac Score's Impact on Patient Management
The MyCARdiac score was developed to provide independent prognostic information based on baseline cardiac markers like LV remodeling (LVEF, LV mass/wall thickness), atherosclerosis (CAC-score), and subclinical congestion (NT-proBNP). Patients classified as high-risk by MyCARdiac exhibited higher serum sBCMA and IL-6 levels, indicating greater disease burden. This high-risk group also experienced impaired CAR T-cell expansion and worse overall outcomes, leading to a need for more aggressive surveillance and tailored management strategies post-infusion to mitigate cardiac complications and optimize treatment efficacy.
Key Takeaway: Early identification of high-risk patients allows for proactive cardiac surveillance and personalized treatment adjustments, improving patient safety and efficacy in cilta-cel therapy.
Calculate Your Potential ROI with AI-Driven Risk Stratification
Estimate the efficiency gains and cost savings for your organization by implementing advanced AI for patient risk assessment and personalized treatment planning.
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
A phased approach to integrating AI-driven cardiac risk stratification into your clinical workflow.
Baseline Cardiac Assessment (Before CAR T-cell Infusion)
Comprehensive echocardiography, pre-treatment CT for CAC scoring, and NT-proBNP measurement to establish baseline cardiac health.
MyCARdiac Score Calculation & Risk Stratification
Integrate LVEF, LVPWd, LVM-Index, CAC, and NT-proBNP to calculate the MyCARdiac score. Classify patients into high-risk (≥2 abnormal parameters) or non-high-risk groups.
Pre-infusion Disease Assessment & Biomarker Analysis
Evaluate sBCMA, EMD, EASIX, and R-ISS to characterize disease burden. Note the correlation of high-risk MyCARdiac with higher sBCMA and EMD.
Post-infusion Surveillance & Monitoring
Implement enhanced cardiac surveillance for high-risk patients. Monitor for early and late ICAHT, sBCMA, and IL-6 levels, and CAR T-cell expansion kinetics to guide supportive care and treatment adjustments.
Personalized Treatment & Outcome Optimization
Tailor post-CAR T-cell therapy management based on MyCARdiac risk, addressing potential cardiac adverse events, optimizing response, and improving long-term PFS and OS.
Ready to Transform Your Enterprise with AI?
Schedule a personalized consultation with our AI specialists to explore how these insights can be tailored to your organization's unique needs and drive measurable impact.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat